The level of VEGF in the ocular tissue is higher in some conditions, such as diabetic retinopathy, venous occlusive disorders, and age-related macular degeneration (2).One of the new treatments for these conditions is to use the intravitreal injection of the anti-VEGF agents like bevacizumab (Avastin®) (3). This evidence concerns the gene VEGFA and diabetic retinopathy.